Valeritas Holdings, Inc. (OTCBB:CYGM) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
its financial results for the first quarter ended March 31, 2017
and an update on the Companys operations for the same period. The
Company is furnishing a copy of the press release, which is
attached hereto as Exhibit 99.1. In accordance with General
Instruction B.2 of Form 8-K, the information included in this
Current Report on Form 8-K (including Exhibit 99.1 hereto), shall
not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference into any filing made
by the Company under the Exchange Act or Securities Act of 1933,
as amended, except as shall be expressly set forth by specific
reference in such a filing.
|
Exhibit
Number
|
Description
|
|
99.1
|
Press release issued by the Company on May 12, 2017
titled Valeritas Reports First Quarter 2017 Financial Results. |
About Valeritas Holdings, Inc. (OTCBB:CYGM)
Valeritas Holdings, Inc., formerly Cleaner Yoga Mat, Inc., is a commercial-stage medical technology company. The Company is focused on developing technologies for Type 2 diabetes. The Company’s product, the V-Go Wearable Insulin Delivery Device (V-Go), is an insulin delivery device that helps patients with Type 2 diabetes requiring insulin to maintain their target blood glucose goals. V-Go is a disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. The Company has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.
